Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Featured

Research Summary
physician with chart and stethoscope
Research Summary
Cliramitug Reduces Cardiac Amyloid Markers in ATTR-CM Extension
09/21/2026
Anthony Calabro, MA
In an open-label extension, cliramitug reduced cardiac amyloid markers over a median 29.3 months in 23 men with ATTR-CM.
09/21/2026
Research Summary
AI technology
Research Summary
Nonrandomized Trial Finds AI Screening Detects ATTR-CM
09/21/2026
Anthony Calabro, MA
In a multisite nonrandomized trial, AI-guided screening identified ATTR-CM in 24 of 50 patients who completed diagnostic testing.
09/21/2026
research summary
cardiovascular system
research summary
Vutrisiran Slows Worsening of Left Atrial Dysfunction in ATTR-CM at 30 Months
09/14/2026
Anthony Calabro, MA
In a post hoc analysis of the phase 3 HELIOS-B trial, vutrisiran reduced worsening of left atrial strain at 30 months among patients with transthyretin amyloidosis with cardiomyopathy.
09/14/2026

Interactive Features

3-in-30
illustration of open book
3-in-30
3-in-30: Recognizing Trends in ATTR-CM
09/09/2026
Anthony Calabro, MA
Recent US claims data offer insight into how transthyretin amyloid cardiomyopathy’s diagnosed incidence, prevalence, and associated clinical burden have changed over time.
09/09/2026

Clinical Insights

ACC.25 Video Interview
Rachel Lampert, MD
ACC.25 Video Interview
ACC.25 Presentation—Arrhythmias in Athletes: Management and Return to Play
04/15/2025
Rachel Lampert, MD
In this video, Rachel Lampert, MD, Robert W. Berliner Professor of Internal Medicine at the Yale School of Medicine, reviews her presentation at the American College of Cardiology 2025 Annual Meeting,...
04/15/2025